Funder
Parker Institute for Cancer Immunotherapy
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference57 articles.
1. West HJ (2015) Immune checkpoint inhibitors. JAMA Oncol 1(1):115–115
2. Eun Y, Kim IY, Sun J-M et al (2019) Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep 9(1):14039. https://doi.org/10.1038/s41598-019-50574-6
3. Abdel-Rahman O, Eltobgy M, Oweira H, Giryes A, Tekbas A, Decker M (2017) Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. Immunotherapy 9(14):1175–1183. https://doi.org/10.2217/imt-2017-0108
4. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol: Off J Am Soc Clin Oncol 30(21):2691–2697. https://doi.org/10.1200/JCO.2012.41.6750
5. Rahma O, Ott P (2018) General principles of immune-related toxicities. In: Marc Ernstoff IP, Robert Caroline, Diab Adi, Hersey Peter (eds) SITC’s guide to managing immunotherapy toxicity. Society for Immunotherapy of Cancer, USA
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献